key: cord-0697635-jc802s1e
authors: Habtemariam, Solomon; Nabavi, Seyed Fazel; Ghavami, Saeid; Cismaru, Cosmin Andrei; Neagoe, Ioana Berindan; Nabavi, Seyed Mohammad
title: Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2
date: 2020-04-30
journal: Pharmacol Res
DOI: 10.1016/j.phrs.2020.104853
sha: 69f7c1f8f526b9e65254be7abe3df248384e7c5e
doc_id: 697635
cord_uid: jc802s1e

nan

Extending the above-mentioned research to SARS-CoV-2, Matsuyama et al. [3] have shown that VeroE6 cells expressing TMPRSS2 are highly susceptible to infection. By using TMPRSS2 overexpression as a tool, the isolation of SARS-CoV-2 is more readily possible [3] . While both ACE2 and TMPRSS2 have been shown to be involved in the entry of SARS-CoV-2 via S protein activation, sera from convalescent SARS patients have been shown to cross-neutralize SARS-CoV2-S-mediated entry into a large number of sensitive cell lines [4] .

This is in addition to the demonstrated inhibitory role of cellular serine protease TMPRSS2 inhibitor in experimental SARS-CoV-2 entry [4] . A recent study on the expression level of TMPRSS2 showed that it is widely expressed in lung tissues while ACE2 is predominantly expressed in a transient secretory cell types or differentiating cells [5] . Activation of TMPRSS2 further plays a key role in other viral respiratory diseases such as influenza A (as with MERS) and inhibition of viral activation by a serine protease inhibitor, the hepatocyte growth factor activator inhibitor type-1 (HAI-1), has been demonstrated in vitro [6] . The putative role of TMPRSS2 as the major activating protease for influenza B virus has also been established [7] .

Based on our knowledge on SARS-CoV and MERS-CoV entry into host cells, the therapeutic potential of TMPRSS2 inhibitors for SARS-CoV-2 can be postulated (Supplemental Figure   1 ). While S1/S2 precleavage was shown to promote S protein activation, processing by TMPRSS2 appears to be critical for infection by these viruses [6] . The detailed mechanism of proteolytic activation of these viruses by TMPRSS2 both at entry and release phases of the infection cycle has been reviewed [1]. Further research is however required to better appreciate the extent by which the proteases and endosomal pathway are involved in viral entry for SARS-CoV-2. The preference of wild-type human coronavirus for cell surface TMPRSS2 when compared to the endosomal route has already been shown [7] . The FDAapproved expectorant/mucolytic agent and cough suppressant, bromhexine hydrochloride, is a well-known potent inhibitor of TMPRSS2 with IC50 equal to 0.75 μM [1]. Since epithelisin is expressed primarily in the apical surface of airway epithelial cells, inhibiting pulmonary TMPRSS2 with bromhexine hydrochloride could represent a prophylactic strategy against the airborne transmission of SARS-CoV2. Because there is no substantial adverse effect, it is reasonable to suggest that this well-known TMPRSS2 inhibitor cold be regarded as a novel prophylactic agent against SARS-CoV-2 infection and research on other potential inhibitors should be encouraged. Clinical trials are needed to evaluate its prophylactic potential against SARS-CoV-2.

There is no conflict of interest

TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections

Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells

TMPRSS11A activates the influenza A virus hemagglutinin and the MERS coronavirus spike protein and is insensitive against blockade by HAI-1

TMPRSS2 is the major activating protease of influenza A virus in primary human airway cells and influenza B virus in human type II pneumocytes